MEDICAL FACILITIES CORP (DR.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:DR - CA58457V5036 - Common Stock
15.87 CAD
-0.07 (-0.44%)
DR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 14 industry peers in the Health Care Providers & Services industry. DR gets an excellent profitability rating and is at the same time showing great financial health properties. DR has a bad growth rate and is valued cheaply. These ratings would make DR suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year DR was profitable.
In the past year DR had a positive cash flow from operations.
Of the past 5 years DR 4 years were profitable.
Each year in the past 5 years DR had a positive operating cash flow.
1.2 Ratios
DR's Return On Assets of 30.18% is amongst the best of the industry. DR outperforms 92.86% of its industry peers.
DR's Return On Equity of 94.43% is amongst the best of the industry. DR outperforms 100.00% of its industry peers.
DR has a Return On Invested Capital of 15.42%. This is amongst the best in the industry. DR outperforms 92.86% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DR is significantly above the industry average of 7.27%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROIC | 15.42% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
1.3 Margins
DR has a better Profit Margin (31.60%) than 92.86% of its industry peers.
DR's Profit Margin has improved in the last couple of years.
DR has a Operating Margin of 15.59%. This is amongst the best in the industry. DR outperforms 100.00% of its industry peers.
DR's Operating Margin has been stable in the last couple of years.
DR has a better Gross Margin (63.75%) than 85.71% of its industry peers.
In the last couple of years the Gross Margin of DR has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% |
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
DR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
DR has less shares outstanding than it did 1 year ago.
The number of shares outstanding for DR has been reduced compared to 5 years ago.
DR has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.37, we must say that DR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DR (1.37) is better than 71.43% of its industry peers.
DR has a debt to FCF ratio of 2.05. This is a good value and a sign of high solvency as DR would need 2.05 years to pay back of all of its debts.
DR has a Debt to FCF ratio of 2.05. This is amongst the best in the industry. DR outperforms 92.86% of its industry peers.
A Debt/Equity ratio of 1.02 is on the high side and indicates that DR has dependencies on debt financing.
DR's Debt to Equity ratio of 1.02 is in line compared to the rest of the industry. DR outperforms 57.14% of its industry peers.
Although DR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Altman-Z | 1.37 |
ROIC/WACC1.86
WACC8.27%
2.3 Liquidity
DR has a Current Ratio of 1.79. This is a normal value and indicates that DR is financially healthy and should not expect problems in meeting its short term obligations.
DR has a better Current ratio (1.79) than 100.00% of its industry peers.
A Quick Ratio of 1.67 indicates that DR should not have too much problems paying its short term obligations.
The Quick ratio of DR (1.67) is better than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
DR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.81%, which is quite impressive.
DR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.68%.
DR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.59% yearly.
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
3.2 Future
The Earnings Per Share is expected to grow by 10.76% on average over the next years. This is quite good.
DR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.10% yearly.
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.62, the valuation of DR can be described as reasonable.
Compared to the rest of the industry, the Price/Earnings ratio of DR indicates a rather cheap valuation: DR is cheaper than 92.86% of the companies listed in the same industry.
DR is valuated cheaply when we compare the Price/Earnings ratio to 26.59, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.31, which indicates a very decent valuation of DR.
Based on the Price/Forward Earnings ratio, DR is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, DR is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 9.31 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DR is valued cheaper than 100.00% of the companies in the same industry.
DR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DR is cheaper than 92.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.23 | ||
| EV/EBITDA | 4.56 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of DR may justify a higher PE ratio.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y14.43%
EPS Next 3Y10.76%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.23%, DR has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 3.28, DR pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.31, DR has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.23% |
5.2 History
The dividend of DR decreases each year by -19.91%.
DR has paid a dividend for at least 10 years, which is a reliable track record.
DR has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-19.91%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
DR pays out 6.72% of its income as dividend. This is a sustainable payout ratio.
DP6.72%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
TSX:DR (12/10/2025, 7:00:00 PM)
15.87
-0.07 (-0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.98%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap286.45M
Revenue(TTM)257.36M
Net Income(TTM)81.33M
Analysts42.22
Price Target16.58 (4.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.23% |
Yearly Dividend0.36
Dividend Growth(5Y)-19.91%
DP6.72%
Div Incr Years1
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.6%
Min EPS beat(2)-7.54%
Max EPS beat(2)6.33%
EPS beat(4)2
Avg EPS beat(4)3.38%
Min EPS beat(4)-24.98%
Max EPS beat(4)39.71%
EPS beat(8)3
Avg EPS beat(8)-25.78%
EPS beat(12)5
Avg EPS beat(12)32.86%
EPS beat(16)7
Avg EPS beat(16)-103.27%
Revenue beat(2)1
Avg Revenue beat(2)-1.3%
Min Revenue beat(2)-4.5%
Max Revenue beat(2)1.91%
Revenue beat(4)1
Avg Revenue beat(4)-6.39%
Min Revenue beat(4)-18.84%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-3.49%
Revenue beat(12)4
Avg Revenue beat(12)-2.43%
Revenue beat(16)5
Avg Revenue beat(16)-2.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)15.63%
EPS NQ rev (3m)15.63%
EPS NY rev (1m)1.24%
EPS NY rev (3m)1.24%
Revenue NQ rev (1m)1.91%
Revenue NQ rev (3m)1.91%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 9.31 | ||
| P/S | 0.8 | ||
| P/FCF | 4.23 | ||
| P/OCF | 3.9 | ||
| P/B | 2.4 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.56 |
EPS(TTM)1.65
EY10.4%
EPS(NY)1.7
Fwd EY10.74%
FCF(TTM)3.75
FCFY23.62%
OCF(TTM)4.07
OCFY25.67%
SpS19.74
BVpS6.61
TBVpS-0.87
PEG (NY)0.28
PEG (5Y)N/A
Graham Number15.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.18% | ||
| ROE | 94.43% | ||
| ROCE | 18.66% | ||
| ROIC | 15.42% | ||
| ROICexc | 19.71% | ||
| ROICexgc | 46.81% | ||
| OM | 15.59% | ||
| PM (TTM) | 31.6% | ||
| GM | 63.75% | ||
| FCFM | 18.99% |
ROA(3y)8.42%
ROA(5y)6.13%
ROE(3y)25.39%
ROE(5y)18.93%
ROIC(3y)16.37%
ROIC(5y)14.6%
ROICexc(3y)21.7%
ROICexc(5y)18.79%
ROICexgc(3y)53.59%
ROICexgc(5y)43.79%
ROCE(3y)19.81%
ROCE(5y)17.76%
ROICexgc growth 3Y35.06%
ROICexgc growth 5Y23.36%
ROICexc growth 3Y18.42%
ROICexc growth 5Y13.1%
OM growth 3Y-0.97%
OM growth 5Y-1.3%
PM growth 3Y78.64%
PM growth 5Y55.2%
GM growth 3Y-0.53%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.02 | ||
| Debt/FCF | 2.05 | ||
| Debt/EBITDA | 1.54 | ||
| Cap/Depr | 25.03% | ||
| Cap/Sales | 1.64% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 93.1% | ||
| Profit Quality | 60.09% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.37 |
F-Score6
WACC8.27%
ROIC/WACC1.86
Cap/Depr(3y)47.79%
Cap/Depr(5y)40.36%
Cap/Sales(3y)2.81%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.81%
EPS 3Y10.86%
EPS 5Y0%
EPS Q2Q%-23.33%
EPS Next Y34.23%
EPS Next 2Y14.43%
EPS Next 3Y10.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.68%
Revenue growth 3Y-5.96%
Revenue growth 5Y-3.59%
Sales Q2Q%-20.29%
Revenue Next Year-20.98%
Revenue Next 2Y-10.85%
Revenue Next 3Y-7.1%
Revenue Next 5YN/A
EBIT growth 1Y-46.1%
EBIT growth 3Y-6.86%
EBIT growth 5Y-4.85%
EBIT Next Year3.8%
EBIT Next 3Y1.99%
EBIT Next 5YN/A
FCF growth 1Y-6.31%
FCF growth 3Y4.28%
FCF growth 5Y3.38%
OCF growth 1Y-24.65%
OCF growth 3Y3.26%
OCF growth 5Y1.55%
MEDICAL FACILITIES CORP / DR.CA FAQ
What is the fundamental rating for DR stock?
ChartMill assigns a fundamental rating of 7 / 10 to DR.CA.
What is the valuation status for DR stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICAL FACILITIES CORP (DR.CA). This can be considered as Undervalued.
Can you provide the profitability details for MEDICAL FACILITIES CORP?
MEDICAL FACILITIES CORP (DR.CA) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for DR stock?
The Price/Earnings (PE) ratio for MEDICAL FACILITIES CORP (DR.CA) is 9.62 and the Price/Book (PB) ratio is 2.4.
Can you provide the dividend sustainability for DR stock?
The dividend rating of MEDICAL FACILITIES CORP (DR.CA) is 5 / 10 and the dividend payout ratio is 6.72%.